retatrutide phase 2 trial weight loss Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized 2a Retatrutide is generating a lot
Description
Nano-RTR-9300 has been engineered to support laboratory investigation of incretin and glucagon receptor interactions, cellular communication networks and receptor-mediated biological processes
[DOI] [PubMed] [Google Scholar] 24.Lincoff M., et al
PMID: 41865922 Spartan Research Library Go Deeper on the Science Browse study indexes, compound comparisons, and protocol stacks in the Spartan Peptides Research Library
2022, PMID: 35658024GLP-1 GLP-1GIP GLP-13GLP-1 1GLP-1 GLP-12 GLP-1Sodhi M, et al
Phase 3 study This study was a 24-week double-blinded, randomized, placebo-controlled trial
